The Claim

Rosuvastatin treatment in adults with low LDL cholesterol and elevated inflammation is associated with a small but statistically significant increase in the incidence of diabetes mellitus compared to placebo, with no further increase observed among those achieving LDL-C levels below 50 mg/dL.

Source: Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
59score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

In adults with low LDL cholesterol and high inflammation, taking rosuvastatin increases the risk of developing diabetes mellitus slightly compared to not taking it, and this increase does not get larger in those whose LDL cholesterol drops below 50 mg/dL.

See the scientific wording

Rosuvastatin treatment in adults with low LDL cholesterol and elevated inflammation leads to a small but statistically significant increase in the incidence of diabetes mellitus compared to placebo, with no further increase observed among those achieving LDL-C levels below 50 mg/dL.

Why this might work

Rosuvastatin blocks the production of certain molecules needed for cells to respond to insulin properly. This makes muscle cells less able to take in sugar from the blood and causes the pancreas to release more insulin than normal, eventually wearing out the insulin-producing cells and leading to higher blood sugar levels.

Supported mechanismbased on 1 study

What the research says

1 study

  1. Study: Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

    Taking rosuvastatin might slightly raise the chance of getting diabetes, but lowering cholesterol even further below 50 mg/dL doesn’t make that risk any worse — and the study found no extra diabetes cases in people who reached that very low level.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.